Women and coronary heart disease risk factors

European Journal of Cardiovascular Prevention & Rehabilitation

Volumn 9, Issue 6, 2002, Pages 315-322

  Bittner, Vera ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

C reactive protein; high density lipoprotein cholesterol; homocysteine; hypercholesterolemia; hypertension; low density lipoprotein cholesterol; menopause; physical activity; physical fitness; smoking; triglycerides

Indexed keywords

CIGARETTE SMOKE; HOMOCYSTEINE; LIPOPROTEIN;

CARDIOVASCULAR RISK; CLUSTER ANALYSIS; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; IMMOBILIZATION; INFLAMMATION; ISCHEMIC HEART DISEASE; MALE; MENOPAUSE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REDUCTION; REVIEW; RISK FACTOR; SMOKING CESSATION; SOCIAL PSYCHOLOGY;

CORONARY DISEASE; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; MENOPAUSE; PERSONALITY; PHYSICAL FITNESS; PREVALENCE; RISK FACTORS; SMOKING; STRESS, PSYCHOLOGICAL; UNITED STATES; WOMEN'S HEALTH;

EID: 0036923815     PISSN: 17418267     EISSN: 17418275     Source Type: Journal    
DOI: 10.1177/174182670200900604     Document Type: Article

References (86)

1. American Heart Association. 2001 Heart and Stroke Statistical Update. Dallas, Texas: American HeartAssociation; 2000.
2. Kannel WB. Risk factors for cardiovascular disease in women. Cardiol Rev 2001; 18: 11–16.
3. Liao Y, McGee DL, Cooper RS. Prediction of coronary heart disease mortality in blacks andwhites: Pooled data from two national cohorts. Am JCardiol 1999; 84: 31–36.
4. Wilson PWF, Kannel WB, Silbershatz H, D'Agostino RB. Clustering of metabolic factors and coronary heartdisease. Arch Intern Med 1999; 159: 1104–1109.
5. Stamler J, Stamler R, Neaton JD, Wentworth D, Daviglus ML, Garside D, et al Low risk-factor profile and long-term cardiovascular andnon-cardiovascular mortality and life expectancy. Findings for five largecohorts of young adult and middle-aged men and women. JAMA 1999; 282: 2012–2018.
6. Wechsler H, Rigotti NA, Gledhill-Hoyt J, Lee H. Increased levels of cigarette use among college students. A causefor national concern. JAMA 1998; 280: 1673–1678.
7. Kesteloot H. Queen Margrethe II and mortality in Danish women. Lancet 2001; 357: 871–872.
8. Wells AJ. Passive smoking as a cause of heart disease. J Am Coll Cardiol 1994; 24: 546–554.
9. Glantz SA, Parmley WW. Passive smoking and heart disease. Mechanisms andrisk. JAMA 1995; 273: 1047–1053.
10. Ciruzzi M, Pramparo P, Esteban O, Rozlosnik J, Tartaglione J, Abecasis B, et al For the Argentine FRICAS Investigators. Case control study ofpassive smoking at home and risk of acute myocardial infarction. ArgentineFRICAS investigators. J Am Coll Cardiol 1998; 31: 797–803.
11. Mayer EJ, Newman B, Quesenberry CP, Friedman GD, Selby JV. Alcohol consumption and insulin concentrations. Circulation 1993; 88: 2190–2197.
12. Fuchs CS, Stampfer MJ, Colditz GA, Giovannucci EL, Manson JAE, Kawachi I, et al Alcohol consumption and mortality among women. N Engl J Med 1995; 332: 1245–1250.
13. Mukamal KJ, Maclure M, Muller JE, Sherwood JB, Mittleman MA. Prior alcohol consumption and mortality following acutemyocardial infarction. JAMA 2001; 285: 1965–1970.
14. Abramson JL, Williams SA, Krumholz HM, Vaccarino V. Moderate alcohol consumption and risk of heart failure amongolder persons. JAMA 2001; 285: 1971–1977.
15. Sacco RL, Elkind M, Boden-Albala B, Lin IF, Kargman DE, Hauser WA, et al The protective effect of moderate alcohol consumption on ischemicstroke. JAMA 1999; 281: 53–60.
16. Williams PT. Physical fitness and activity as separate heart disease riskfactors: A meta-analysis. Med Sci Sports Exerc 2001; 33: 754–761.
17. Hu FB, Stampfer MJ, Colditz GA, Ascherio A, Rexrode KM, Willett WC, et al Physical activity and risk of stroke in women. JAMA 2000; 283: 2961–2967.
18. Lee IM, Rexrode KM, Cook NR, Manson JAE, Buring JE. Physical activity and coronary heart disease inwomen. JAMA 2001; 285: 1447–1454.
19. Lemaitre RN, Siscovick DS, Raghunathan TE, Weinmann S, Arbogast P, Lin DY. Leisure-time physical activity and the risk of primary cardiacarrest. Arch Intern Med 1999; 159: 686–690.
20. US Department of Health and HumanServices. Physical Activity, and Health. A Report of theSurgeon General. Atlanta, Georgia: US Department of Health and Human Services. Centers forDisease Control and Prevention, National Center for Chronic DiseasePrevention and Health Promotion; 1996.
21. Lahad A, Heckbert SR, Koepsell TD, Psaty BM, Patrick DL. Hostility, aggression and the risk of nonfatal myocardialinfarction in postmenopausal women. J Psychosom Res 1997; 43: 183–195.
22. Suarez EC, Bates MP, Harralson TL. The relation of hostility to lipids and lipoproteins in women:Evidence for the role of antagonistic hostility. AnnBehav Med 1998; 20: 59–63.
23. Whiteman MC, Deary IJ, Lee AJ, Fowkes FGR. Submissiveness and protection from coronary heart disease in thegeneral population: Edinburgh Artery Study. Lancet 1997; 350: 541–545.
24. Rutledge T, Reis SE, Olson M, Owens J, Kelsey SF, Pepine CJ, et al History of anxiety disorders is associated with a decreasedlikelihood of angiographic coronary artery disease in women with chest pain:The WISE study. J Am Coll Cardiol 2001; 37: 780–785.
25. Paterniti S, Zureik M, Ducimetiere P, Touboul PJ, Feve JM, Alperovitch A. Sustained anxiety and 4-year progression of carotidatherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 136–141.
26. Marmott MG, Bosma H, Hemingway H, Brunner E, Stansfeld S. Contribution of job control and other risk factors to socialvariations in coronary heart disease incidence. Lancet 1997; 350: 235–239.
27. Orth Gomez K, Wamala SP, Horsten M, Schenck-Gustafsson K, Schneiderman N, Mittleman MA. Martial stress worsens prognosis in women with coronary heartdisease. The Stockholm Female Coronary Risk Study. JAMA 2000; 284: 3008–3014.
28. Schulz R, Beach SR. Caregiving as a risk factor for mortality. The Caregiver HealthEffects Study. JAMA 1999; 282: 2215–2219.
29. Ferketich AK, Schwartzbaum JA, Frid DJ, Moeschberger ML. Depression as an antecedent to heart disease among women and menin the NHANES I study. Arch Intern Med 2000; 160: 1261–1268.
30. Whooley MA. Browner WS for the Study of Osteoporotic Fractures ResearchGroup. Association between depressive symptoms and mortality in olderwomen. Arch Intern Med 1998; 158: 2129–2135.
31. Mendes de Leon CF, Krumholz HM, Seeman TS, Vaccarino V, Williams CS, Kasl SV, et al Depression and risk of coronary heart disease in elderly men andwomen. New Haven EPESE, 1982–1991. ArchIntern Med 1998; 158: 2341–2348.
32. Schulz R, Beach SR, Ives DG, Martire LM, Ariyo AA, Kop WJ. Association between depression and mortality in older adults. TheCardiovascular Health Study. Arch Intern Med 2000; 160: 1761–1768.
33. Wassertheil-Smoller S, Applegate WB, Berge K, Chang CJ, Davis BR, Grimm R, et al, For the SHEP Cooperative Research Group. Changein depression as a precursor of cardiovascular events. Arch Intern Med 1996; 156: 553–561.
34. Barrett-Connor E. Sex differences in coronary heart disease. Why are women sosuperior? The 1995 Ancel Keys Lecture. Circulation 1997; 95: 252–264.
35. Tunstall-Pedoe H. Myth and paradox of coronary risk and themenopause. Lancet 1998; 351: 1425–1427.
36. Hu FB, Grodstein F, Hennekens CH, Colditz GA, Johnson M, Manson JAE, et al Age at natural menopause and risk of cardiovasculardisease. Arch Intern Med 1999; 159: 1061–1066.
37. Jacobsen BK, Knutsen SF, Fraser GE. Age at natural menopause and total mortality and mortality fromischemic heart disease: The Adventist Health Study. J Clin Epidemiol 1999; 52(4):303–307.
38. Hak AE, Pols HAP, van Hemert AM, Hofman A, Witteman JCM. Progression of aortic calcification is associated with metacarpalbone loss during menopause. A population-based longitudinalstudy. Arterioscler Thromb Vasc Biol 2000; 20: 1926–1931.
39. Lloyd-Jones DM, Evans JC, Larson MG, O'Donnell CJ, Wilson PWF, Levy D. Cross-classification of JNC VI blood pressure stages and riskgroups in the Framingham Heart Study. Arch InternMed 1999; 159: 2206–2212.
40. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic and cardiovascular risks.US Population Data. Arch Intern Med 1993; 153: 598–615.
41. Glynn RJ, Chae CU, Guralnik JM, Taylor JO, Hennekens CH. Pulse pressure and mortality in older people. Arch Intern Med 2000; 160: 2765–2772.
42. Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistelli M, et al Ambulatory blood pressure. An independent predictor of prognosisin essential hypertension. Hypertension 1994; 24: 793–801.
43. Staessen JA, Thijs L, Fagard R, O'Brien ET, Clement D, de Leeuw PW, et al For the Systolic Hypertension in Europe Trial Investigators.Predicting cardiovascular risk using conventional versus ambulatory bloodpressure in older patients with systolic hypertension. JAMA 1999; 282: 539–546.
44. Kannel WB, D'Agostino RB, Sibershatz H. Blood pressure and cardiovascular morbidity and mortality ratesin the elderly. Am Heart J 1997; 134: 758–763.
45. Guyeffier F, Boutitie F, Boissel JP, Pocock S, Coope J, Cutler J, et al Effect of antihypertensive drug treatment on cardiovascularoutcomes in women and men. Ann Intern Med 1997; 126: 761–767.
46. Staessen JA, Gasowski J, Wang JG, Thijs L, Den Hond E, Boissel JP, et al Risks of untreated and treated isolated systolic hypertension inthe elderly: Meta-analysis of outcome trials. Lancet 2000; 355: 865–872.
47. Wassertheil-Smoller S, Anderson G, Psaty BM, Black HR, Manson JAE, Wong N, et al Hypertension and its treatment in postmenopausal women. Baselinedata from the Women's Health Initiative. Hypertension 2000; 36: 780–789.
48. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High BloodPressure. US Department of Health and Human Services. National Institutes of Health, National Heart, Lung, and Blood Institute.NIH Publication No. 98–4080, November 1997.
49. Manolio TA, Pearson TA, Wenger NK, Barrett-Connor E, Payne GH, Harlan WR. Cholesterol and heart disease in older persons and women. Reviewof an NHLBI workshop. Ann Epidemiol 1992; 2: 161–176.
50. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovasculardisease independent of high-density lipoprotein cholesterol level: Ameta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3: 213–219.
51. Bittner V, Simon JA, Fong J, Blumenthal RS, Newby K, Stefanick ML. Correlates of high HDL cholesterol among women with coronaryheart disease. Am Heart J 2000; 139: 288–296.
52. Agerholm-Larsen B, Nordestgaard BG, Steffensen R, Jensen G, Tybjaerg-Hansen A. Elevated HDL cholesterol is a risk factor for ischemic heartdisease in white women when caused by a common mutation in the cholesterylester transfer protein gene. Circulation 2000; 101: 1907–1912.
53. LaRosa JC. Lipoproteins and coronary artery disease risk inwomen. J Myocardial Ischemia 1991; 3: 35–42.
54. Jenner JL, Ordovas JM, Lamon-Fava S, Schaefer MM, Wilson PWF, Castelli WP, et al Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. Circulation 1993; 87: 1135–1141.
55. Seman LJ, DeLuca C, Jenner JL, Cupples LA, McNamara JR, Wilson PWF, et al Lipoprotein (a)-cholesterol and coronary heart disease in theFramingham Heart Study. Clin Chem 1999; 45: 1039–1046.
56. Nishino M, Malloy MJ, Naya-Vigne J, Russell J, Kane JP, Redberg RF. Lack of association of lipoprotein (a) levels with coronarycalcium deposits in asymptomatic postmenopausal women. J Am Coll Cardiol 2000; 35: 314–320.
57. Orth-Gomez K, Mittleman MA, Schenck-Gustafson K, Wamala SP, Eriksson M, Belkic K, et al Lipoprotein (a) as a determinant of coronary heart disease inyoung women. Circulation 1997; 95: 329–334.
58. Shlipak MG, Simon JA, Vittinghoff E, Lin F, Barrett-Connor E, Knopp RH, et al Estrogen and progestin, lipoprotein (a), and the risk ofrecurrent coronary heart events after menopause. JAMA 2000; 283: 1845–1852.
59. Campeau L, Hunninghake DB, Knatterud GL, White CW, Dmonaski M, Forman SA, et al, And Post CABG Trial Investigators. Aggressivecholesterol lowering delays saphenous vein graft atherosclerosis in women,the elderly, and patients with associated risk factors. Circulation 1999; 99: 3241–3247.
60. La Rosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: A meta-analysis ofrandomized controlled trials. JAMA 1999; 282: 2340–2346.
61. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al For the Myocardial Ischemia Reduction With Aggressive CholesterolLowering (MIRACL) Study Investigators. JAMA 2001; 285: 1711–1718.
62. Expert Panel on Detection, Evaluation, andTreatment of High Blood Cholesterol in Adults. Executive summary of the third report of the NationalCholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation,and Treatment of High Blood Cholesterol in Adults (Adult Treatment PanelIII). JAMA 2001; 285: 2486–2497.
63. Tallova J, Tomandl J, Bicikova M, Hill M. Changes of plasma total homocysteine levels during the menstrualcycle. Eur J Clin Invest 1999; 29: 1041–1044.
64. Hak AE, Polderman KH, Westendorp ICD, Jakobs C, Hofman A, Witteman JCM, et al Increased plasma homocysteine after menopause. Atherosclerosis 2000; 149: 163–168.
65. Morris MS, Jacques PF, Slehub J, Rosenberg IH. Total homocysteine and estrogen status indicators in the ThirdNational Health and Nutrition Examination Survey. AmJ Epidemiol 2000; 152: 140–148.
66. Gerhard GT, Malinow MR, DeLoughery TG, Evans AJ, Sexton G, Connor SL, et al Higher total homocysteine concentrations and lower folateconcentrations in premenopausal black women than in premenopausal whitewomen. Am J Clin Nutr 1999; 70: 252–260.
67. Kark JD, Selhub J, Adler B, Gofin J, Abramson JH, Friedman G, et al Non-fasting plasma total homocysteine level and mortality inmiddle-aged and elderly men and women in Jerusalem. Ann Intern Med 1999; 131: 321–330.
68. Bostom AG, Rosenberg IH, Silbershatz H, Jacques PF, Selhub J, D'Agostino RB, et al Non-fasting plasma total homocysteine levels and stroke incidencein elderly persons: The Framingham Study. Ann InternMed 1999; 131: 352–355.
69. Ridker PM, Manson JAE, Buring JE, Shih J, Matias M, Hennekens CH. Homocysteine and risk of cardiovascular disease amongpostmenopausal women. JAMA 1999; 281: 1817–1821.
70. Aronow WS, Ahn C. Increased plasma homocysteine is an independent predictor of newcoronary events in older persons. Am J Cardiol 2000; 86: 346–347.
71. Hoogeveen EK, Kostense PJ, Jakobs C, Dekker JM, Nijpels G, Heine RJ, et al Hyperhomocysteinemia increases risk of death, especially in TypeII diabetes. Five-year follow-up of the Hoorn Study. Circulation 2000; 101: 1506–1511.
72. Foody JAM, Milberg JA, Robinson K, Pearce GL, Jacobsen DW, Sprecher DL. Homocysteine and lipoprotein (a) interact to increase CAD risk inyoung men and women. Arterioscler Thromb Vasc Biol 2000; 20: 493–499.
73. Loria CM, Ingram DD, Feldman JJ, Wright JD, Madans JH. Serum folate and cardiovascular disease mortality among US menand women. Arch Intern Med 2000; 160: 3258–3262.
74. Rimm EB, Willett WC, Hu FB, Sampson L, Colditz GA, Manson JAE, et al Folate and vitamin B6 from diet and supplements in relation torisk of coronary heart disease among women. JAMA 1998; 279: 359–364.
75. Brouwer IA, van Dusseldorp M, Thomas CMG, Duran M, Hautvast JGAJ, Eskes TKAB, et al Low-dose folic acid supplementation decreases plasma homocysteineconcentrations: A randomized trial. Am J Clin Nutr 1999; 69: 99–104.
76. Wald DS, Bishop L, Wald NJ, Law M, Hennessy E, Weir D, et al Randomized trial of folic acid supplementation and serumhomocysteine levels. Arch Intern Med 2001; 161: 695–700.
77. Ford ES, Giles WH. Serum C-reactive protein and fibrinogen concentrations andself-reported angina pectoris and myocardial infarction. Findings fromNational Health and Nutrition Examination Survey III. J Clin Epidemiol 2000; 53: 95–102.
78. Ridker PM, Hennekens CH, Buring JE, Rifal N. C-reactive protein and other markers of inflammation in theprediction of cardiovascular disease in women. NEngl J Med 2000; 342: 836–843.
79. Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, et al Relationship of C-reactive protein to risk of cardiovasculardisease in the elderly. Arterioscler Thromb VascBiol 1997; 17: 1121–1127.
80. Tracy RP, Psaty BM, Macy E, Bovill EG, Cushman M, Cornell ES, et al Lifetime smoking exposure affects the association of C-reactiveprotein with cardiovascular disease risk factors and sub-clinical disease inhealthy elderly subjects. Arterioscler Thromb VascBiol 1997; 17: 2167–2176.
81. Hak AE, Stehouwer CDE, Bots ML, Polderman KE, Schalkwijk CG, Westendorp ICD, et al Associations of C-reactive protein with measures of obesity,insulin resistance, and sub-clinical atherosclerosis in healthy middle-agedwomen. Arterioscler Thromb Vasc Biol 1999; 19: 1986–1991.
82. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obeseadults. JAMA 1999; 282: 2131–2135.
83. Tataru MC, Heinrich J, Junker R, Schulte H, von Eckardstein A, Assmann G, et al C-reactive protein and the severity of atherosclerosis inmyocardial infarction patients with stable angina pectoris. Eur Heart J 2000; 21: 1000–1008.
84. Redberg RF, Rifai N, Gee L, Ridker PM. Lack of association of C-reactive protein and coronary calcium byelectron beam computed tomography in postmenopausal women: Implications forcoronary artery disease screening. J Am Coll Cardiol 2000; 36: 39–43.
85. Lagrand WK, Visser CA, Hermens WT, Niessen HWM, Verheugt FWA, Wolbink GJ, et al C-reactive protein as a cardiovascular risk factor. More than anepiphenomenon?. Circulation 1999; 100: 96–102.
86. Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, et al Effect of postmenopausal hormones on inflammation-sensitiveproteins. The Postmenopausal Estrogen/Progestin Intervention(PEPI) Study. Circulation 1999; 100: 717–722.